Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule

Inclusion criteria

• Age range 20 to 54 years, Body mass index of ≥19 and ≤26 healthy male volunteers
• Able to participate in all procedure
• SBP 90-140 mmHg, DBP 60-90 mmHg, Pulse rate 55-95 times/min
• Have given written informed consent

Exclusion criteria

• Have history of significant cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, musculoskeletal neurologic disease
• Have history of gastrointestinal disease(Crohn's disease, gastrointestinal ulcer) or surgery(except for Appendectomy, Hernia)
• Have allergy or hypersensitivity to carvedilol or any component of the formulation(aspirin, antibiotics)
• Have history of drug abuse. A positive test for any drug(amphetamine, barbiturates, cocaine, opiates, benzodiazepines, THC, methadone, ect.) included in the urine drug screen.
• Have herbal drug within 30days prior to the first IP administration, have ETC within 14days prior to the first IP administration, have OTC 7days prior to the first IP administration.
• Have diet which may influence on the absorption, distribution, metabolism or excretion of drug(s), (Drinking over 1L of grapefruit juice within 7days prior to the first IP administration)
• Have received an investigational drug within 60 days prior to the first IP administration
• Have donated whole blood within 60 days prior or donation plasma within 30 days prior to the first IP administration
• Have any metabolic enzyme including or inhibiting drugs like barbiturates within 30 days prior to the first IP administration.
• A heavy caffeine/alcohol consumer or a heavy smoker(caffeine > 5 units/days. alcohol >21 units/week (1 unit=pure alcohol 10mL), Cigarette > 10 Cigarettes/day) or alcohol abuse.
• Positive for Hepatitis B, Hepatitis C, HIV or syphilis